ArticleJournal of orthopaedic surgery and research2026
Clinical significance and regulatory mechanism of miR-4284 in lumbar intervertebral disc degeneration.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLumbar disc degeneration (LDD) is one of the main causes of low back pain. This study investigates the role of miR-4284 and its target, CYCS, in LDD pathogenesis.
methodsSerum levels of miR-4284 and CYCS were measured in 121 LDD patients and 79 healthy controls. The clinical diagnostic and predictive value of miR-4284 was evaluated using ROC curve analysis and logistic regression. Stimulated human nucleus pulposus (NP) cells with LPS and transfected with miR-4284 mimic/inhibitor or CYCS overexpression vector. Cell viability, inflammatory factors (IL-1β, TNF-α), and oxidative stress markers (MDA, T-AOC) were assessed. A luciferase reporter assay confirmed targeting. Western blot analysis was performed to detect the expression of apoptosis-related proteins (Bax, Bcl-2) and mitochondrial function-related proteins (PGC-1α, SOD2).
resultsIn LDD patients, serum miR-4284 expression was significantly downregulated (P < 0.001) and exhibited good diagnostic value (AUC = 0.831). miR-4284 might serve as a protective factor for LDD (OR = 0.100), showing negative correlations with Pfirrmann grading, ODI, and VAS scores (P < 0.001). Luciferase assays confirmed that CYCS was a direct target of miR-4284. In LPS-stimulated NP cells, miR-4284 overexpression alleviated inflammation and oxidative stress while enhancing cell viability. Concurrently, overexpression of CYCS not only completely reversed the protective effects mediated by miR-4284 but also exacerbated cellular apoptosis and mitochondrial dysfunction, thereby synergistically promoting the pathological progression of LDD.
conclusionmiR-4284 is significantly decreased in LDD and may serve as a protective biomarker. By targeting CYCS, it alleviates inflammation and oxidative stress, inhibits apoptosis, and mitigates mitochondrial dysfunction in NP cells, thereby potentially delaying LDD progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.